Advertisement
Correction

Correction: ErbB-Inhibitory Protein: A Modified Ectodomain of Epidermal Growth Factor Receptor Synergizes with Dasatinib to Inhibit Growth of Breast Cancer Cells

DOI: 10.1158/1535-7163.MCT-10-0671 Published September 2010

In this article (Mol Cancer Ther 2010;9:1503–14), which was published in the June 1, 2010 issue of Molecular Cancer Therapeutics (1), the labels of Figs. 1B and C were not aligned correctly. The correct Figure 1 appears here. The online article has been changed to reflect this correction and no longer matches the print.

    Reference

    1. ↵
      1. Nautiyal J,
      2. Yu Y,
      3. Aboukameel A,
      4. et al
      . ErbB-inhibitory protein: A modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells. Mol Cancer Ther 2010;9:1503–14.
      OpenUrlAbstract/FREE Full Text
    Back to top
    Molecular Cancer Therapeutics: 9 (9)
    September 2010
    Volume 9, Issue 9

    Sign up for alerts

    View this article with LENS

    Open full page PDF
    Article Alerts
    Email Article
    Citation Tools
    Correction: ErbB-Inhibitory Protein: A Modified Ectodomain of Epidermal Growth Factor Receptor Synergizes with Dasatinib to Inhibit Growth of Breast Cancer Cells
    Mol Cancer Ther September 1 2010 (9) (9) 2637; DOI: 10.1158/1535-7163.MCT-10-0671
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

    Jump to section

    Advertisement